Henlius Gets Fourth Chinese Biosimilar With Bevacizumab Nod
Cites ‘Huge Demand’ For Avastin Rival In China; Also Developing Ophthalmic Version
Shanghai Henlius Biotech has celebrated its fourth Chinese biosimilar approval with the NMPA’s endorsement of its bevacizumab biosimilar. The company is also working on an ophthalmic version to treat wAMD.
You may also be interested in...
Chinese player Shanghai Henlius Biotech has out licensed semi-exclusive rights to some of its biosimilars in Brazil again, shortly after signing a major deal covering 16 Latin American countries.
Henlius has reshuffled its C-suite, with chairman Qiyu Chen stepping down from the role to take up a position as non-executive director and CEO Wenjie Zhang poised to step into his shoes.
After listing on the Hong Kong stock exchange in late 2019, China’s Tot Biopharm has delivered its first antibody drug approval, with its Pusintin (bevacizumab) biosimilar to Avastin.